Toni Choueiri, MD

Medical Oncology

Toni Choueiri, MD

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

View Full Profile

Related Videos

Kidney Cancer Highlights from ESMO 2022 Video

Kidney Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022

Toni Choueiri, MD Shares the Latest Data From COSMIC-313 Video

Toni Choueiri, MD Shares the Latest Data From COSMIC-313

Kidney Cancer triplet slows progression in advanced disease when compared to immunotherapy combo (nivolumab + ipilimumab).

COVID-19 and Cancer: Breakthrough Infections Video

COVID-19 and Cancer: Breakthrough Infections

New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.

Kidney Cancer Research at ESMO Video

Kidney Cancer Research at ESMO

Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.

COVID-19 and Cancer: Screenings Rebound but Study Finds Disparities Video

COVID-19 and Cancer: Screenings Rebound but Study Finds Disparities

Cancer screenings rebounded after a dramatic decline in the first months of the COVID-19 pandemic, but a new study found an increase in disparities among some screening tests during the pandemic.

COVID-19 Vaccine Study in Cancer Patients Video

COVID-19 Vaccine Study in Cancer Patients

Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research Video

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Video

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study Video

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study

Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.